MedPath

Tagged News

Clinical Trial System Faces Sustainability Crisis as Costs Soar and Workforce Shrinks

AI
  • The clinical trial workforce has declined dramatically, with investigators dropping from 128,303 to 116,948 globally and coordinators falling from 56,036 to 40,472 between 2017-2024.
  • Oncology trial costs have reached unsustainable levels, averaging $30 million for Phase 1 trials and nearly $60 million for Phase 3 studies, with total drug development costs hitting $2.3 billion.
  • Only 5-8% of eligible patients participate in clinical trials, while 60-70% of trial sites fail to meet enrollment targets, creating a bottleneck that threatens future drug development.
  • AI-driven platforms and decentralized trial models offer potential solutions to address recruitment inefficiencies and expand access to underserved rural communities.

Microsoft Launches BioEmu AI System to Accelerate Drug Discovery Through Protein Simulation

AIDrug Discovery
  • Microsoft has introduced BioEmu, an AI system that can predict protein structural changes and movements in hours rather than the years typically required for traditional computer simulations.
  • The system achieves prediction errors of less than 1 kcal/mol and correlation scores above 0.6 on large test datasets, demonstrating high accuracy in matching real-world experimental protein stability data.
  • BioEmu can generate thousands of protein structures per hour using just one GPU, offering a scalable and cost-effective alternative to traditional molecular dynamics simulations.
  • The AI system can identify cryptic binding pockets in proteins, which are hidden drug target sites that could lead to the development of new therapeutic compounds.

OneTouch-PAT Breast Imaging System Demonstrates Promise in Early Clinical Tests with AI-Enhanced Detection

AI
  • University at Buffalo researchers developed OneTouch-PAT, a pain-free breast imaging system that combines photoacoustic and ultrasound imaging to complete scans in under one minute without painful compression.
  • The system tested on 61 breast cancer patients and 4 healthy individuals produced clear AI-powered 3D images showing unique vascular patterns for different cancer subtypes including Luminal A, Luminal B, and Triple-Negative Breast Cancer.
  • OneTouch-PAT eliminates operator error through automated scanning and shows particular promise for women with dense breast tissue, where traditional mammography is less accurate.
  • The technology uses deep learning networks to process imaging data and provides more detailed tumor visualization compared to operator-dependent photoacoustic and ultrasound systems.

Broken String Biosciences and BioLizard Partner to Develop AI-Powered SafeGuide for CRISPR Gene Editing Safety

Gene EditingAI
  • Broken String Biosciences and BioLizard have announced the development of SafeGuide, an AI tool designed to select safer guide RNAs for CRISPR gene editing applications.
  • The collaboration aims to replace current trial-and-error approaches that take one to two years and result in drug costs exceeding $4 million per patient.
  • The project is supported by a $935,000 grant from the competitive Eurostars-3 program, part of the European Partnership on Innovative SMEs.
  • SafeGuide will integrate Broken String's INDUCE-seq platform data with BioLizard's AI algorithms to predict high-efficacy, low-risk guide RNA designs.

Fifty1 AI Labs Completes Landmark Phase III REVIVE Trial for Long COVID Treatment

AI
  • Fifty1 AI Labs successfully completed the REVIVE Adaptive Platform Trial, the largest and most rigorous Long COVID study to date, enrolling over 600 participants across multiple global sites.
  • The Phase III, multicenter, adaptive, randomized, double-blind, placebo-controlled trial represents the first adaptive platform trial to demonstrate clear treatment benefit for Long COVID using repurposed medicines.
  • The trial was powered by Fifty1 AI Labs' proprietary Bayesian and Predictive Platform, which integrates clinical trial data, patient outcomes, and drug interaction profiles to optimize drug candidate selection.
  • Long COVID affects approximately 400 million people globally and 15% of COVID-19 survivors, with an estimated economic burden exceeding USD 1 trillion annually.

A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial

NCT06128967RecruitingPhase 3
Cardresearch
Posted 10/18/2023

TandemAI and Perpetual Medicines Merge to Advance AI-Driven Small Molecule and Peptide Drug Discovery

AIDrug Discovery
  • TandemAI and Perpetual Medicines have completed a strategic merger to create an expanded AI and physics-based drug discovery platform covering both small molecules and peptides.
  • The combined company will leverage TandemAI's proven track record with over 150 pharmaceutical partners and Perpetual's computational peptide discovery platform to accelerate therapeutic development.
  • More than ten client programs from TandemAI are expected to reach clinical trials within the next 12 months, demonstrating the commercial viability of their AI-driven approach.
  • The merger positions the combined entity to capitalize on the growing commercial opportunity in peptide therapeutics, particularly following the success of GLP-1, IL-23, and PCSK9 drug classes.

Renovaro Biosciences Converts $9.7M Debt to Equity, Strengthens AI-Driven Drug Discovery Platform

AIPrecision MedicineDrug Discovery
  • Renovaro Inc. (NASDAQ:RENB) announced that senior debt holders agreed to convert approximately $9.7 million of outstanding debt into equity through the issuance of 53.6 million shares at $0.30 per share.
  • The debt conversion significantly enhances the company's balance sheet by eliminating debt obligations and interest payments, providing greater financial flexibility for growth initiatives.
  • The biotechnology company focuses on AI-driven precision medicine, developing innovative therapies and diagnostics in oncology, infectious disease, and autoimmune disorders using machine learning integrated with biomedical research.

Xaira Therapeutics Appoints Jeff Jonker as President and COO to Scale AI-Driven Drug Discovery Platform

AIDrug Discovery
  • Xaira Therapeutics has appointed biotech veteran Jeff Jonker as President and Chief Operating Officer to help scale its AI-enabled drug discovery platform and drive the next phase of growth.
  • Jonker brings over two decades of leadership experience, having served as CEO of Belharra Therapeutics and Ambys Medicines, and President of NGM Biopharmaceuticals where he formed strategic partnerships with Merck.
  • The appointment comes as Xaira aims to fundamentally reimagine drug discovery by integrating machine learning, biological insight, and therapeutic development to accelerate medicine discovery.
  • Xaira recently published the X-Atlas/Orion dataset, profiling over 8 million single cells as the largest publicly available genome-wide Perturb-seq dataset to power next-generation foundation models in biology.

Revolution Medicines Partners with Iambic Therapeutics in $25M AI-Driven Drug Discovery Collaboration for RAS-Addicted Cancers

AIDrug DiscoveryOncologyTargeted Therapy
  • Revolution Medicines and Iambic Therapeutics announced a multi-year collaboration in July 2025 to develop novel drug candidates using AI-driven discovery platforms targeting RAS-addicted cancers.
  • The partnership leverages Iambic's NeuralPLexer protein structure prediction model and PropANE neural network, trained on Revolution's proprietary data to accelerate discovery of therapies for challenging oncology targets.
  • Under the agreement, Iambic will receive up to $25 million through upfront payments, performance-based milestones, and R&D reimbursements, while both companies retain rights to exclusive targets.
  • The collaboration aims to address RAS mutations that drive approximately 30% of all cancers but remain among the most challenging drug targets for conventional discovery methods.

Phesi CEO Warns of Impending Phase 3 Trial Failures Due to Site Oversaturation and Complex Design

AI
  • Phesi analysis reveals Phase 3 trials across multiple indications face avoidable failure due to overly complex design and lack of real-world data integration.
  • Atopic dermatitis trials exemplify the crisis, with recruiting sites surging 205% in four years while one California investigator manages 14 concurrent AD studies.
  • AI-powered data analytics could simplify trial metrics and improve site selection, with EASI and %BSA showing near-perfect correlation in AD patient populations.
  • The company's Digital Patient Profile analysis suggests opportunities to reduce patient burden without compromising scientific rigor through smarter endpoint selection.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.